What is Amphista Therapeutics?
Founded in 2017, Amphista Therapeutics is a pioneering biopharmaceutical enterprise dedicated to the development of first-in-class therapeutics. The company specializes in leveraging the body's innate biological mechanisms to selectively and efficiently degrade disease-causing proteins. By focusing on these natural pathways, Amphista aims to provide novel treatment options for conditions that have historically proven resistant to conventional pharmacological approaches. Its market position is defined by its innovative approach to protein homeostasis, which has attracted significant interest from both venture capital firms and global pharmaceutical leaders.
How much funding has Amphista Therapeutics raised?
Amphista Therapeutics has raised a total of $60.5M across 2 funding rounds:
Series A
$7.5M
Series B
$53M
Series A (2020): $7.5M with participation from BioMotiv, Advent Venture Partners LLP, Scottish Investment Bank, and European Investment Fund
Series B (2022): $53M led by Forbion Capital, Gilde Healthcare company, Novartis, Dementia Discovery Fund, and Eli Lilly and Company Pvt. Ltd.
Key Investors in Amphista Therapeutics
BioMotiv
BioMotiv is a mission-driven accelerator associated with The Harrington Project, focused on advancing early-stage breakthrough discoveries from research institutions into viable medicines.
Scottish Investment Bank
The Scottish Investment Bank is a national economic development agency and a non-departmental public body of the Scottish Government, supporting business growth and innovation.
European Investment Fund
The European Investment Fund facilitates access to finance for European SMEs and infrastructure projects, providing debt and equity funding to foster technological innovation.
What's next for Amphista Therapeutics?
With the recent infusion of $53M, Amphista Therapeutics is well-positioned to accelerate its clinical pipeline and expand its research capabilities. The strategic focus will likely center on advancing lead candidates through preclinical and early clinical trials, while simultaneously refining its platform technology to identify new therapeutic targets. As the company scales, it will continue to leverage its partnerships with institutional investors and industry giants to navigate the complex regulatory and scientific landscape of modern drug discovery. The focus remains on delivering transformative outcomes for patients by unlocking the potential of targeted protein degradation at scale.
See full Amphista Therapeutics company page
